Back to Search
Start Over
Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy
- Source :
- Journal of Hepatology
- Publication Year :
- 2018
-
Abstract
- Chronic hepatitis delta represents the most severe form of chronic viral hepatitis. The current treatment of hepatitis delta virus (HDV) infection consists of the use of interferons and is largely unsatisfactory. Several new compounds are currently in development for the treatment of HDV infection. However, surrogate markers that can be used to develop clinical endpoints in HDV infection are not well defined. In the current manuscript, we aimed to evaluate the existing data on treatment of HDV infection and to suggest treatment goals (possible "trial endpoints") that could be used across different clinical trials.<br />NA
- Subjects :
- 0301 basic medicine
Medicine
Gastroenterology and hepatology
Hepatitis D, Chronic
Polymers
Pyridines
viruses
Medizin
Virus
03 medical and health sciences
Lipopeptides
0302 clinical medicine
Chronic hepatitis
Piperidines
Nucleic Acids
Clinical endpoint
Humans
Clinical Trials as Topic
Hepatitis B Surface Antigens
Hepatology
business.industry
Surrogate endpoint
virus diseases
biochemical phenomena, metabolism, and nutrition
medicine.disease
Hepatitis D
Treatment efficacy
Clinical trial
030104 developmental biology
Treatment Outcome
Liver
Treatment endpoints
Surrogate marker
New treatment approaches
Immunology
RNA, Viral
030211 gastroenterology & hepatology
business
Viral hepatitis
Biomarkers
Subjects
Details
- ISSN :
- 16000641
- Volume :
- 70
- Issue :
- 5
- Database :
- OpenAIRE
- Journal :
- Journal of hepatology
- Accession number :
- edsair.doi.dedup.....12c1dce31cb43b79745da1c6e86d5958